DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Tipifarnib
Tipifarnib
The Application of a Characterized Pre-Clinical
Options for the Treatment of Gemcitabine-Resistant Advanced Pancreatic Cancer
LEUKEMIA CHEMOTHERAPY REGIMENS (Part 1 of 2) the Selection, Dosing, and Administration of Anti-Cancer Agents and the Management of Associated Toxicities Are Complex
(DAC) Followed by Clofarabine, Idarubicin, and Cytarabine (CIA) in Acute Leukemia 2012-1064
Drug Name Plate Number Well Location % Inhibition, Screen Axitinib 1 1 20 Gefitinib (ZD1839) 1 2 70 Sorafenib Tosylate 1 3 21 Cr
Corporate Overview May 2017
(12) United States Patent (10) Patent No.: US 8,911,786 B2 Desai Et Al
Spotlight Review
A Phase I, Pharmacokinetic, and Biological Study of The
(12) Patent Application Publication (10) Pub. No.: US 2009/0226431 A1 Habib (43) Pub
Chronic Myelogenous Leukemia: a Review and Update of Current and Future Therapy
Day Dosing of the Proteasome Inhibitor Carfilzomib in Patients with Relapsed Or Refractory Multiple Myeloma Or Lymphoma
Spectrum Pharmaceuticals Appoints Steven M. Fruchtman, MD, an Industry Veteran, As Vice President of Clinical Development
Preliminary Results from a Phase 2 Trial of Tipifarnib in HRAS Mutant Head & Neck Squamous Cell Carcinomas (HNSCC)
Novel Drugs for Older Patients with Acute Myeloid Leukemia
Activity of Bortezomib in Adult De Novo and Relapsed Acute Myeloid Leukemia
Cancer Gene Expression Profiles Associated with Clinical Outcomes To
(Tipifarnib, Zarnestraм) in Human Breast
Top View
Treatment of Relapsed and Refractory Multiple Myeloma
Division of Vital Statistics, Mortality Data Table Page 1 of 147
Gene Networks Constructed Through Simulated Treatment Learning Can Predict Proteasome Inhibitor Benefit in Multiple Myeloma
Tipifarnib in Head and Neck Squamous Cell Carcinoma with HRAS Mutations the Following Represents Disclosure Information Provided by Authors of This Manuscript
A Robust Gene Expression Signature to Predict Proteasome Inhibitor Benefit in Multiple 2 Myeloma 3 Joske Ubels1,2,3,4, Pieter Sonneveld3, Martin H
Clofarabine (Clolar™, Evoltra™): Mode of Action
Chemical Structure-Related Drug-Like Criteria of Global Approved Drugs
Chronic Myeloid Leukemia, Version 2.2021
Computationally Predicting Clinical Drug Combination Efficacy With
Recent Advances in the Cellular and Molecular Understanding of Myelodysplastic Syndromes: Implications for New Therapeutic Approaches
Study Protocol and Statistical Analysis Plan
A Pilot Study of Adjuvant Doxorubicin and Cyclophosphamide Followed by Paclitaxel and Sorafenib in Women with Node-Positive Or High-Risk Early-Stage Breast Cancer
Beyond NFKB Inhibition Alone and the Emerging Role of Combination
Exploration of Mutations in Erythroid 5-Aminolevulinate Synthase That
Affimed Dec 7 2018 – Horwitz – Guest Clinical Expert 1
Proposed Diagnostic Criteria for Classical Chronic Myelomonocytic Leukemia (CMML), CMML Variants and Pre-CMML Conditions
NCI Experimental Therapeutics Clinical Trials Network(ETCTN)
Non ABL-Directed Inhibitors As Alternative Treatment Strategies For